Cyclosporin randomized clinical trial

Drug interactions In a randomized, double-blind study, Zenapax or placebo was added to an immunosuppressive regimen of cyclosporine, mycophenolate mofetil, and steroids to assess tolerability, pharmacokinetics, and drug interactions. The addition of Zenapax did not result in an increased incidence of adverse events or a change in the types of adverse events reported. The following medications have been administered in clinical trials with Zenapax with no incremental increase in adverse reactions cyclosporine, mycophenolate mofetil, ganciclovir, acyclovir, azathioprine, and corticosteroids. 

Unfortunately, most of the current management strategies for uveitis are borne out of anecdotal and/or empirical approaches. Few if any randomized, controlled, clinical trials exist regarding conventional therapy for uveitis indeed, only a handful of such trials have been identified in the current literature, and most of those focus on the use of systemic cyclosporine. 

The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990 27 591-605. 

Infliximab is approved for treatment of rheumatoid arthritis and Crohn s disease, but has been studied for use in psoriasis. One double-blind, randomized, placebo-controUed clinical trial studied the effectiveness and safety of infliximab in patients with moderate to severe psoriasis. A good response was seen in 82% and 91% of patients treated with infliximab 5 mg/kg or 10 mg/kg, respectively. Median time to response for all patients receiving infliximab was 4 weeks. The investigators concluded that patients treated with infliximab had a high degree of clinical improvement with rapid response rate, similar to that observed with cyclosporine therapy. ... 

---